These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15027125)

  • 1. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response.
    Di Modugno F; Bronzi G; Scanlan MJ; Del Bello D; Cascioli S; Venturo I; Botti C; Nicotra MR; Mottolese M; Natali PG; Santoni A; Jager E; Nisticò P
    Int J Cancer; 2004 May; 109(6):909-18. PubMed ID: 15027125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes.
    Jäger D; Karbach J; Pauligk C; Seil I; Frei C; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2005 Dec; 5():11. PubMed ID: 16335914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method.
    Nakatsura T; Senju S; Ito M; Nishimura Y; Itoh K
    Eur J Immunol; 2002 Mar; 32(3):826-36. PubMed ID: 11870627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
    J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
    Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
    Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
    Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
    Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T; Irie RF; Morton DL; Hoon DS
    Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer.
    Jaramillo A; Majumder K; Manna PP; Fleming TP; Doherty G; Dipersio JF; Mohanakumar T
    Int J Cancer; 2002 Dec; 102(5):499-506. PubMed ID: 12432553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
    Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
    Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
    Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS
    Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
    Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers.
    Bharat A; Benshoff N; Fleming TP; Dietz JR; Gillanders WE; Mohanakumar T
    Breast Cancer Res Treat; 2008 Aug; 110(3):453-63. PubMed ID: 17874294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.